← InSilico Medicine Cayman TopCo overview

InSilico Medicine Cayman TopCo vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InSilico Medicine Cayman TopCo (3696.HK)

Q2 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

June 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Latest
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.